Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 73 | ECE2021 | Next issue

European Congress of Endocrinology 2021

Online
22 May 2021 - 26 May 2021

Card image cap
The European Congress of Endocrinology provides a global platform for the international endocrine community to discuss the latest advances in the field.

Oral Communications

Oral Communications 15: Late Breaking

ea0073oc15.1 | Oral Communications 15: Late Breaking | ECE2021

Differential steroidomic profiles of human visceral and subcutaneous adipose tissue before and after bariatric surgery-induced weight loss

Laforest Sofia , Denham Scott , Denver Nina , Biertho Laurent , Homer Natalie Z.M. , Andrew Ruth , Tchernof Andre

BackgroundObesity is closely associated with impaired adipose tissue function. Although bariatric surgery is the treatment of choice for severe obesity and its related conditions, there are conflicting data on the reversal of adipose tissue dysfunction after surgery-induced weight loss. We hypothesise that local steroid hormone availability influences fat deposition or mobilisation and that these changes track with weight loss improvements, because plasm...

ea0073oc15.2 | Oral Communications 15: Late Breaking | ECE2021

Screening for mutations in isolated central hypothyroidism reveals a novel mutation in insulin receptor substrate 4 (IRS4)

Patyra Konrad , Kristiina Makkonen , Maria Haanpää , Karppinen Sinikka , Viikari Liisa , Jorma Toppari , Mary Pat Reeve , Kero Jukka

BackgroundCentral hypothyroidism (CeH) is a rare condition affecting approximately 1:16000 – 100 000 individuals. Congenital forms can harm the normal development if not detected and treated promptly. The clinical and biochemical diagnosis especially of the isolated CeH can be challenging. The cases are not usually detected in the neonatal screening, which, in most countries, are focused on detection of the more prevalent primary hypothyroidism. Unt...

ea0073oc15.3 | Oral Communications 15: Late Breaking | ECE2021

Targeting PI3K and CDKs as effective therapeutic option for PPGLs in vitro and in vivo

Gulde Sebastian , Martino Daniela De , Mohr Hermine , Satam Swapna , Foscarini Alessia , Nölting Svenja , Pellegata Svenja

Pheochromocytoma and Paraganglioma, collectively referred to as PPGLs, are rare, mostly benign neuroendocrine tumors arising from chromaffin cells of the adrenal gland or of extra-adrenal sites, respectively. Surgery is the first-line therapy for localized PPGLs. However, up to 17% of PPGLs show metastatic spread, and for these cases there is no curative treatment. Therefore, the identification of novel therapeutic approaches for advanced PPGLs is highly clinically relevant. W...

ea0073oc15.4 | Oral Communications 15: Late Breaking | ECE2021

Identification of a dose range for once daily oral paltusotine in patients with acromegaly that maintains IGF-1 levels when switching from long-acting somatostatin receptor ligand therapy

Gordon Murray B. , Gadelha Monica , Toth Miklos , Doknic Mirjana , Mezosi Emese , Randeva Harpal , Marmon Tonya , Luo Rosa , Monahan Michael , Madan Ajay , Struthers Scott , Krasner Alan

Long-acting somatostatin receptor ligands (LA-SRLs) are a first line medical treatment for acromegaly but require monthly parenteral administration. Paltusotine (CRN00808) is a nonpeptide, small molecule somatostatin type 2 (SST2) receptor agonist with high oral bioavailability (70%), suitable for once daily, oral dosing. The recently reported results of the ACROBAT Edge study (NCT03789656) suggest that patients with acromegaly treated with injected SRLs can switch to once dai...

ea0073oc15.5 | Oral Communications 15: Late Breaking | ECE2021

The Importance of maternal thyroid hormone for programming the cardiovascular system in the male offspring

Pedaran Mehdi , Oelkrug Rebecca , Mittag Jens

Thyroid hormones play an essential role for the embryonal development of the cardiovascular system including its central control mechanisms. Particularly the latter critically depends on maternal thyroid hormone, as the embryo doesn’t produce own thyroid hormone until late in pregnancy. However, the precise window of action has remained undetermined, and it is therefore unclear whether alterations in maternal thyroid hormone directly affect the offspring’s cardiac fu...

ea0073oc15.6 | Oral Communications 15: Late Breaking | ECE2021

Genetic polymorphism (IP-10/CXCL10) and diabetes mellitus type 1

Pashkunova Sylvia , Daneva Teodora , Vassilev Dimitar , Kostadinov Nikolay , Tsonev Stefan , Vangelova Joana , Vitanova Detelina

IntroductionThe development of Diabetes mellitus type 1 (DMT1) is considered as an autoimmune pro-inflammatory process. Human enteroviruses are thought to be also a cause. These viruses influence beta cells and cause expression of immunological factors. The affected cells destroy the related beta cells. The aim of the work is to study the genetic polymorphisms in IP-10/CXCL10 and its receptors CXCR3 and TLR4 in order to predict expression of DMT1.<p ...